Relationship between the initial dose of micafungin and its efficacy in patients with candidemia

Journal of Infection and Chemotherapy

Volumn 13, Issue 4, 2007, Pages 208-212

  Ota, Yasuo ^a   Tatsuno, Keita ^a   Okugawa, Shu ^a   Yanagimoto, Shintaro ^a   Kitazawa, Takatoshi ^a   Fukushima, Atsuhito ^a   Tsukada, Kunihisa ^a   Koike, Kazuhiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

C. parapsilosis; Candida; Candidemia; Echinocandin; Micafungin

Indexed keywords

MICAFUNGIN;

ADULT; AGED; ARTICLE; CANDIDEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MYCOSIS;

EID: 34548178201     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-007-0522-y     Document Type: Article

References (25)

1. DW Denning 2003 Echinocandin antifungal drugs Lancet 362 9390 1142 51
2. JR Graybill 2001 Hitting a new target with echinocandins. Why chase something else? Curr Opin Investig Drugs 2 468 71
3. FC Odds AJ Brown NA Gow 2003 Antifungal agents: mechanisms of action Trends Microbiol 11 272 9
4. J Mora-Duarte R Betts C Rotstein AL Colombo L Thompson-Moya J Smietana 2002 Comparison of caspofungin and amphotericin B for invasive candidiasis N Engl J Med 347 2020 9
5. NA Kartsonis J Nielsen CM Douglas 2003 Caspofungin: the first in a new class of antifungal agents Drug Resist Update 6 197 218
6. L Ostrosky-Zeichner D Kontoyiannis J Raffalli KM Mullane J Vazquez EJ Anaissie 2005 International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia Eur J Clin Microbiol Infect Dis 24 654 61
7. JA van Burik V Ratanatharathorn DE Stepan CB Miller JH Lipton DH Vesole 2004 Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation Clin Infect Dis 39 1407 16
8. S Kohno T Masaoka H Yamaguchi T Mori A Urabe A Ito 2004 A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan Scand J Infect Dis 36 372 9
9. K Pettengell J Mynhardt T Kluyts W Lau D Facklam D Buell 2004 Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent Aliment Pharmacol Ther 20 475 81
10. B Jarvis DP Figgitt LJ Scott 2004 Micafungin Drugs 64 969 82 discussion p. 983-4
11. NP Wiederhold RE Lewis 2003 The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy Expert Opin Investig Drugs 12 1313 33
12. S Tawara F Ikeda K Maki Y Morishita K Otomo N Teratani 2000 In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi Antimicrob Agents Chemother 44 57 62
13. L Ostrosky-Zeichner JH Rex PG Pappas RJ Hamill RA Larsen HW Horowitz 2003 Antifungal susceptibility survey of 2000 bloodstream Candida isolates in the United States Antimicrob Agents Chemother 47 3149 54
14. AH Groll D Mickiene V Petraitis R Petraitiene KH Ibrahim SC Piscitelli 2001 Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits Antimicrob Agents Chemother 45 3322 7
15. PA Warn A Sharp G Morrissey DW Denning 2002 In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis J Antimicrob Chemother 50 1071 4
16. N de Wet A Llanos-Cuentas J Suleiman E Baraldi EF Krantz M Della Negra 2004 A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients Clin Infect Dis 39 842 9
17. J Hiemenz P Cagnoni D Simpson S Devine N Chao J Keirns 2005 Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant Antimicrob Agents Chemother 49 1331 6
18. RW Chang S Jacobs B Lee 1988 Predicting outcome among intensive care unit patients using computerised trend analysis of daily Apache II scores corrected for organ system failure Intensive Care Med 14 558 66
19. LA Mermel BM Farr RJ Sherertz II Raad N O'Grady JS Harris 2001 Guidelines for the management of intravascular catheter-related infections Clin Infect Dis 32 1249 72
20. National Committee for Clinical Laboratory Standards (2002) Reference method for broth dilution antifungal susceptibility testing of yeast. Approved Standard M27-A2. NCCLS W, PA, USA
21. MP Pai RS Turpin KW Garev 2007 Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia Antimicrob Agents Chemother 51 35 9
22. J Garbino L Kolarova P Rohner D Lew P Pichna D Pittet 2002 Secular trends of candidemia over 12 years in adult patients at a tertiary care hospital Medicine (Baltimore) 81 425 33
23. P Eggimann J Garbino D Pittet 2003 Epidemiology of Candida species infections in critically ill non-immunosuppressed patients Lancet Infect Dis 3 685 702
24. PG Pappas JH Rex J Lee RJ Hamill RA Larsen W Powderly 2003 A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients Clin Infect Dis 37 634 43
25. JH Rex PG Pappas AW Karchmer J Sobel JE Edwards S Hadley 2003 A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects Clin Infect Dis 36 1221 8